Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis

• Published in: BMC gastroenterology Vol. 21; no. 1; p. 490
• Main Authors: Tang, Shan, Zhang, Jing, Mei, Ting-Ting, Zhang, Wen-Yan, Zheng, Su-Jun, Yu, Hai-Bin
• Format: Journal Article
• Language: English
• Published: England BioMed Central 20.12.2021; BMC
• Subjects: 17-Hydroxysteroid Dehydrogenases - genetics; Alleles; Bias; Carcinoma, Hepatocellular - genetics; Dehydrogenases; Fatty liver; Gastroenterology; Genotype & phenotype; Hepatitis; Hepatocellular carcinoma; HSD17B13 rs72613567:TA allelic variant; Humans; Liver cancer; Liver disease; Liver diseases; Liver Neoplasms - genetics; Meta-analysis; Mutation; Non-alcoholic Fatty Liver Disease - genetics; Odds Ratio; Population; Population studies; Sensitivity analysis; Statistical analysis; Tat protein; United States > US; HSD17B13 rs72613567:TA allelic variant; Liver disease; Meta-analysis
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-021-02067-y

To assess the association of HSD17B13 rs72613567:TA allelic variant with liver disease, we performed the current review and meta-analysis. Seven studies were identified by a search of CNKI,CBM,MEDLINE, PubMed, EMBASE, and CENTRAL databases from inception to November 2021. Odds ratios (ORs) with 95% confidence interval (CI) were calculated using random effects model or fixed effects model based on the between-study heterogeneity. The Stata 14.0 software was employed for data analysis. Statistical analysis showed that the HSD17B13 rs72613567:TA allelic variant can decrease the risk of hepatocellular carcinoma(HCC) in nonalcoholic fatty liver disease (NAFLD) patients, alcoholic fatty liver disease (ALD) patients and viral hepatitis patients (TA vs T OR = 0.766, 95% CI = 0.682-0.860, P = 0.000; TATA + TAT vs TT OR = 0.755, 95% CI = 0.645-0.885, P = 0.001) or healthy controls(TA vs T OR = 0.649, 95% CI = 0.431-0.977, P = 0.038). Besides, the HSD17B13 rs72613567:TA allelic variant can also provide protection from nonalcoholic fatty liver disease (NAFLD) not only in entire population (TA vs T OR = 0.669, 95% CI = 0.524-0.856, P = 0.001) but also in healthy people (TA vs T OR = 0.600, 95% CI = 0.464-0.777, P = 0.000). No significant publication bias found in this airticle. The present findings suggest HSD17B13 rs72613567:TA allelic variant can reduce the risk of HCC and NAFLD in the entire population studied.